分红方面，赛分科技A股上市后累计派现1707.50万元。 机构持仓方面，截止2025年6月30日，赛分科技十大流通股东中，南方科创板3年定开混合（506000）位 居第一大流通股东，持股79.11万股，相比上期减少89.36万股。银河医药混合A（011335）退出十大流 通股东之列。 责任编辑：小浪快报 资料显示，苏州赛分科技股份有限公司位于中国(江苏)自由贸易试验区苏州片区苏州工业园区集贤街11 号，成立日期2009年3月16日，上市日期2025年1月10日，公司主营业务涉及研发和生产用于药物分析检 测和分离纯化的液相色谱材料。主营业务收入构成为：工业纯化板块33.10%，工业纯化板块:填料 32.65%，分析色谱板块16.73%，分析色谱板块:色谱柱13.31%，分析色谱板块:填料3.13%，分析色谱板 块:其他0.29%，工业纯化板块:其他0.27%，其他(补充)0.18%，工业纯化板块:色谱柱0.18%，服务 0.15%。 截至6月30日，赛分科技股东户数1.05万，较上期减少4.63%；人均流通股3779股，较上期增加4.86%。 2025年1月-6月，赛分科技实现营业收入1.83亿元，同比增长19 ...

苏州赛分科技股份有限公司 证券代码：688758 证券简称：赛分科技 苏州赛分科技股份有限公司 2025 年第一次临时股东会会议资料 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会 议的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》、《上市公司股东会规则》以及《苏州赛分科技股份有限公司 章程》 （以下简称"《公司章程》"） 、《苏州赛分科技股份有限公司股东会议事规则》 等相关规定，苏州赛分科技股份有限公司（以下简称"公司"）特制定 2025 年第 一次临时股东会会议须知： 一、 为保证本次会议的严肃性和正常秩序，切实维护股东的合法权益，出席 会议的股东及股东代理人须在会议召开前 30 分钟到会议现场办理登记手续，并请 按规定出示股票账户卡、身份证/护照原件或加盖公章的营业执照复印件、授权委 托书等，经验证后领取会议资料，方可出席会议。公司有权拒绝不符合条件的人 士进入会场。 二、 会议开始后，会议签到应当终止，由会议主持人宣布现场出席会议的股 东和代理人人数及所持有的表决权数量，签到终止之后到场的股东无权参与现场 投票表决。 三、 会议按照会议 ...

2025 年 9 月 苏州赛分科技股份有限公司 2025 年第一次临时股东会会议资料 目录 证券代码：688758 证券简称：赛分科技 苏州赛分科技股份有限公司 2025 年第一次临时股东会会议资料 | 2025 | 年第一次临时股东会会议须知 | 1 | | --- | --- | --- | | 2025 | 年第一次临时股东会议程 | 3 | | 2025 | 年第一次临时股东会会议议案 | 5 | | | 议案一： | 关于修订《募集资金管理制度》的议案 5 | | | 议案二： | 关于补选非独立董事的议案 6 | 2025年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会 议的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》、《上市公司股东会规则》以及《苏州赛分科技股份有限公司 章程》（以下简称"《公司章程》"）、《苏州赛分科技股份有限公司股东会议事规则》 等相关规定，苏州赛分科技股份有限公司（以下简称"公司"）特制定 2025 年第 一次临时股东会会议须知： 一、 为保证本次会议的严肃性和正常秩序，切实维护股 ...

截至2025年8月22日收盘，赛分科技（688758）报收于20.15元，较上周的19.1元上涨5.5%。本周，赛分 科技8月22日盘中最高价报21.5元。8月18日盘中最低价报19.11元。赛分科技当前最新总市值83.92亿 元，在化学制药板块市值排名71/150，在两市A股市值排名2197/5152。 本周关注点 股本股东变化 近日赛分科技披露，截至2025年6月30日公司股东户数为1.05万户，较3月31日减少508.0户，减幅为 4.63%。户均持股数量由上期的3.8万股增加至3.98万股，户均持股市值为68.29万元。 公司公告汇总 苏州赛分科技股份有限公司2025年半年度报告摘要，公司代码：688758，公司简称：赛分科技。公司 2025年半年度拟以实施权益分派股权登记日登记的总股本为基数分配利润，本次利润分配方案如下：公 司拟向全体股东每股派发现金红利人民币0.026元（含税）。截至2025年6月30日公司总股本416464084 股，以此计算合计拟派发现金红利人民币10828066.18元（含税），占2025年半年度归属于上市公司股 东净利润的20.18%，不送红股，不进行资本公积转增股本。该 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][8]. Core Insights - The company has shown stable revenue growth with a significant increase in net profit, driven by effective cost control and increased government subsidies [10]. - The analysis segment has stable growth, while the industrial purification segment has experienced rapid growth, particularly in the GLP-1 drug purification market [10]. - The trend of domestic substitution is becoming established, and the company is making orderly progress in overseas market expansion [10]. Financial Performance Summary - Revenue for 2023 is projected at 2.45 billion yuan, with a year-on-year growth of 15.2%. By 2027, revenue is expected to reach 5.82 billion yuan, reflecting a growth rate of 22.7% [6]. - The net profit attributable to the parent company is forecasted to grow from 520 million yuan in 2023 to 1.85 billion yuan in 2027, with a compound annual growth rate of 33.1% [6]. - Earnings per share are expected to increase from 0.13 yuan in 2023 to 0.44 yuan in 2027 [6]. Segment Performance Summary - The analysis chromatography segment is expected to generate revenue of 610 million yuan in the first half of 2025, reflecting a year-on-year growth of 7.57% [10]. - The industrial purification segment is projected to achieve revenue of 1.20 billion yuan in the first half of 2025, with a year-on-year growth of 28.59% [10]. - The company has accumulated 87 projects in clinical phase III and commercial production stages through domestic substitution by the end of June 2025 [10].

Core Viewpoint - The A-share pharmaceutical sector has shown significant growth this year, with nearly 90% of stocks rising, and 56 stocks doubling in price, indicating a recovery in the industry after a period of capital winter [1][4]. Group 1: Market Performance - The A-share market has seen a trading volume exceeding 2 trillion yuan for six consecutive days, with the pharmaceutical sector leading the gains [1]. - Among the stocks, Shuyou Shen (300204.SZ) has the highest cumulative increase of 6.44 times, followed by Saifen Technology (688758.SH) with 3.57 times, and Guangsheng Tang (300436.SZ) with 3.55 times [1]. - Other notable stocks with over 100% increase include Chao Yan Co. (301602.SZ), Yipin Hong (300723.SZ), and several others, indicating a strong upward trend in the sector [1]. Group 2: Industry Dynamics - The recent bullish trend in pharmaceutical stocks is attributed to the recognition of domestic pharmaceutical companies' innovation capabilities [2]. - The industry faced a capital winter due to homogeneous competition and lower-than-expected returns on innovative drugs, but the current performance suggests a recovery [4]. - The number of successful outbound transactions for domestic innovative drugs has reached a record, with 50 projects and a total transaction value exceeding 48.4 billion USD [5]. Group 3: Policy Support - The National Medical Insurance Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, signaling strong governmental backing for the industry [7]. - The introduction of dual directories for medical insurance and commercial insurance for innovative drugs represents a significant innovation in the policy landscape, enhancing the payment capabilities for innovative drugs [7]. - The current policy environment is seen as favorable for the growth of the innovative drug sector, contributing to a positive outlook for the industry [7].

Group 1: Insurance Asset Management - The development trend of China's insurance asset management is anchored by insurance capital and supported by third-party services, focusing on enhancing equity research capabilities and alternative investments in high-dividend and national strategic areas [5][7] - The insurance asset management industry in China has gone through three stages: initial establishment in 2003, policy relaxation from 2012 to 2017, and accelerated market-oriented reforms since 2018, leading to increased competitiveness [5][6] - The current state of the industry shows continuous scale expansion but a decline in concentration, with insurance capital accounting for 74% of funding sources and a preference for fixed-income assets [6][7] Group 2: Midea Group - Midea Group is positioned as a leading player in the home appliance industry, with flexible mechanisms and a focus on global expansion and supply chain efficiency, which are expected to enhance its competitive edge [9][10] - The company has a strong dividend policy, with a current dividend yield of 4.8%, and is projected to achieve net profits of 43.9 billion, 47.6 billion, and 51.8 billion yuan from 2025 to 2027, corresponding to PE ratios of 13, 12, and 11 [9][10] - Midea's strategic focus on B-end business and continuous investment in core components and integrated solutions is expected to contribute to long-term growth [10] Group 3: Sifen Technology - Sifen Technology's industrial purification business is rapidly growing, with a projected revenue of 384.2 million, 464.7 million, and 558.3 million yuan from 2025 to 2027, reflecting a year-on-year growth of 21.8%, 21.0%, and 20.1% [12][13] - The company achieved a revenue of 183 million yuan in the first half of 2025, with a net profit of 54 million yuan, indicating a year-on-year growth of 19.8% and 40.9% respectively [12][13] - The growth in the GLP-1 related products segment is particularly notable, with a revenue increase of 177.5% [12][13] Group 4: Huafeng Aluminum - Huafeng Aluminum's performance in the first half of 2025 showed resilience despite industry challenges, with revenue of 5.964 billion yuan, a year-on-year increase of 20.87% [15][16] - The company is awaiting the launch of its Chongqing Phase II project, which is expected to alleviate bottlenecks in hot-rolled production and drive future growth [16][17] - Adjustments to the company's EPS forecasts for 2025-2027 are made to 1.29, 1.50, and 1.88 yuan, with corresponding PE ratios of 14, 12, and 10, maintaining a "buy" rating [16][17] Group 5: Tongcheng Travel - Tongcheng Travel reported a revenue of 9.05 billion yuan in the first half of 2025, reflecting an 11.5% year-on-year increase, with adjusted EBITDA growing by 35.2% [19][20] - The core online travel platform business is experiencing rapid growth, with significant contributions from hotel management services [19][20] - The company aims to enhance its international market presence and strengthen its hotel management business as a second growth curve [20]

Core Viewpoint - The financial performance of Saifen Technology (688758) for the first half of 2025 shows significant growth in revenue and net profit, indicating a strong operational performance and effective cost management [1]. Financial Performance Summary - Total revenue for the first half of 2025 reached 183 million yuan, a year-on-year increase of 19.77% compared to 152 million yuan in 2024 [1]. - Net profit attributable to shareholders was 53.66 million yuan, up 40.91% from 38.08 million yuan in the previous year [1]. - The gross profit margin decreased to 70.6%, down 5.16% year-on-year, while the net profit margin improved to 29.55%, an increase of 16.17% [1]. - The company reported a significant increase in cash and cash equivalents, which rose by 130.36% to 314 million yuan due to the proceeds from its IPO [1][4]. Accounts Receivable and Liabilities - Accounts receivable increased by 33.37% to 96.60 million yuan, indicating a growing sales volume but also potential cash flow concerns [1]. - Interest-bearing liabilities rose by 5.48% to 6.53 million yuan, reflecting a modest increase in debt levels [1]. Cost and Expense Analysis - Total selling, administrative, and financial expenses amounted to 44.35 million yuan, accounting for 24.28% of revenue, a slight increase of 0.3% year-on-year [1]. - Operating expenses increased due to higher sales promotion costs and management expenses, which rose by 16.31% and 19.81% respectively [3]. Cash Flow and Investment - Net cash flow from operating activities increased by 36.32%, driven by higher sales and improved collection of receivables [3]. - The net cash flow from financing activities surged by 3388.35% due to the influx of funds from the IPO [4]. Market Position and Investment Insights - The company has a return on invested capital (ROIC) of 6.49%, indicating average capital efficiency, with a historical median ROIC of 4.08% since its listing [5]. - Analysts project the company's performance for 2025 to reach 102 million yuan in revenue, with an average earnings per share of 0.24 yuan [6]. Fund Holdings - The largest fund holding Saifen Technology is the Invesco CSI Star Market 50 ETF, which has recently increased its position [7].

Investment Rating - The report maintains an "Accumulate" rating for the company [2][6]. Core Insights - The company reported a revenue of 183 million yuan for the first half of 2025, representing a year-on-year growth of 19.77%. The net profit attributable to shareholders was 54 million yuan, up 40.91% year-on-year, and the net profit excluding non-recurring items was 47 million yuan, reflecting a 22.08% increase [3][6]. - In Q2 2025, the company achieved a revenue of 99 million yuan, which is a 30.81% increase year-on-year and an 18.49% increase quarter-on-quarter. The net profit attributable to shareholders for Q2 was 30 million yuan, showing a remarkable year-on-year growth of 110.68% and a quarter-on-quarter increase of 25.94% [6]. - The rapid growth in net profit is attributed to increased revenue and effective cost absorption due to business scale expansion, leading to a significant improvement in overall net profit margin [6]. - The company is focused on providing comprehensive analytical chromatography and industrial purification solutions for global biopharmaceutical companies, aiming to become the most trusted partner in the biopharmaceutical sector [6]. - The company is accelerating its R&D innovations, optimizing various coating and modification processes, and has developed new products that meet market demands, showcasing its unique core technology platforms in chromatographic media preparation [6][7]. Financial Projections - The company is projected to achieve total revenue of 384 million yuan in 2025, with net profit expected to reach 97 million yuan, and EPS forecasted at 0.23 yuan. For 2026, total revenue is estimated at 468 million yuan, with net profit of 120 million yuan and EPS of 0.29 yuan [7].

证券代码：688758 证券简称：赛分科技 公告编号：2025-030 苏州赛分科技股份有限公司 根据中国证监会颁布的《上市公司独立董事管理办法》有关规定，审计委员 会成员应当为不在上市公司担任高级管理人员的董事。为完善公司治理结构，保 障公司董事会审计委员会规范运作，公司董事会拟对第二届董事会审计委员会部 分成员进行调整，即公司董事长、总经理黄学英先生不再担任公司第二届董事会 审计委员会委员，由公司独立董事徐锋先生担任审计委员会委员，与彭淑贞女士、 梁永伟先生共同组成公司第二届董事会审计委员会，任期自本次董事会审议通过 之日起至公司第二届董事会任期届满之日止。 本次调整后，公司董事会审计委员会构成为：彭淑贞、梁永伟、徐锋。公司 董事会战略委员会、提名委员会、薪酬与考核委员会委员保持不变。 特此公告。 苏州赛分科技股份有限公司 关于补选非独立董事及调整董事会审计委员会委员 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州赛分科技股份有限公司（以下简称"公司"或"赛分科技"）于 2025 年 8 月 16 日召开 ...